CANCER GENE THERAPY PROGRAM

本计划项目的目标是开发和测试有效的手段， 用基因转移技术治疗人类癌症。具体 目的是开发和应用引入细胞因子基因的策略， 肿瘤细胞，以诱导特异性和有效的免疫反应。 攻击病人现有的肿瘤方案的组成部分 项目包括： 1.细胞因子基因治疗人黑色素瘤和肾癌 疗法 2.膀胱癌细胞因子基因治疗的临床应用 3.造血干细胞的基因治疗 4.载体设计和评价 5.行政核心 最初的一系列临床试验将使用辐照过的IL-2产生细胞， 人黑色素瘤和肾癌细胞的HLA-A2型注射到 具有相同HLA类型的晚期疾病患者。的潜在 同种异体方法的优点包括促炎性 影响自体肿瘤识别。随后的审判将涉及 用IL-2基因转导的自体黑素瘤或肾癌细胞。 一项黑色素瘤试验将涉及使用法师-1黑色素瘤- 相关抗原为了保护人体淋巴造血系统 系统，将进行耐药基因转移到 所述造血干细胞和计划被开发以构建小鼠 具有完全人类淋巴造血系统的模型，用于临床前 人类基因治疗的研究。发展研究也将 进行细胞因子基因治疗人膀胱癌的研究， 已知对免疫疗法有反应且能够 直接观察和访问。新载体和载体-细胞因子基因 将开发更高效、有效和安全的组合 肿瘤细胞因子基因治疗的研究进展。

The goal of this Program Project is to develop and test effective means for treating human cancer using gene transfer technology. The specific aim is to develop and apply strategies or introducing cytokine genes into tumor cells in order to induce a specific and effective immunologic attack on a patient's existing tumor. The components of the Program Project are: 1. Treatment of Human Melanoma and Renal Cell Carcinoma by Cytokine Gene Therapy. 2. Bladder Cancer Cytokine Gene Therapy: Human Application 3. Gene Therapy Using the Hematopoietic Stem Cell 4. Vector Design and Evaluation 5. Administration Core The initial series of clinical trials will use irradiated IL-2-producing human melanoma and renal cancer cells of HLA-A2 type injected into patients of the same HLA types with advanced disease. The potential advantages of the allogeneic approach include the pro-inflammatory effects on autologous tumor recognition. Subsequent trials will involve autologous melanoma or renal cancer cells transduced with the IL-2 gene. One trial in melanoma will involve the use of the MAGE-1 melanoma- associated antigen. In order to protect the human lymphohematopoietic system, studies will be conducted of drug resistance gene transfer into the hematopoietic stem cell and a plan is developed to construct a mouse model with a completely human lymphohematopoietic system for preclinical studies of human gene therapy. Developmental studies will also be conducted to apply cytokine gene therapy to human bladder carcinoma, an important human tumor known to respond to immunotherapy and capable of direct observation and access. New vectors and vector-cytokine gene combinations will be developed for more efficient, effective, and safe approaches to cytokine gene therapy of cancer.